DTR (DTR) News
Follow DTR (DTR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
DoJ and DoW move to Support Resumption of Operations at Colosseum
SAN BERNARDINO, CA / / September 28, 2026 / Dateline Resources Limited ASX:DTROTC:DTREFFWB:YE1 (Dateline or the Company) advises that the Federal Defendants in the National Parks Conservation Association proceedings have
NEWS | Sep 28, 2026, 12:08 PM UTC
M
Dateline Resources files motion to stay injunction
Dateline Resources Limited has filed a motion to stay a preliminary injunction, as a first step toward resuming work at its Colosseum Gold and Rare Earth Project in California.
REGULATION | Sep 21, 2026, 12:01 PM UTC
L
Dateline Resources moves to lift Colosseum injunction
MACRO | Sep 21, 2026, 01:31 AM UTC
L
DiagnosTear posts final study results for TeaRx red eye biomarker IgE
DiagnosTear Technologies reported final clinical study results for TeaRx(TM) red eye testing for total tear IgE as a biomarker for allergic conjunctivitis. The study reported 89% sensitivity and 83.3% specificity versus
EQUITY | Sep 10, 2026, 12:31 PM UTC
L
DiagnosTear files FDA pre-submission for TeaRx red eye test
DiagnosTear Technologies says it has submitted a pre-submission request to the U.S. Food and Drug Administration for TeaRx(TM), its red eye diagnostic test.
REGULATION | Sep 03, 2026, 11:06 AM UTC